Complement, a Therapeutic Target in Diabetic Kidney Disease
Currently available treatments of diabetic kidney disease (DKD) remain limited despite improved understanding of DKD pathophysiology. The complement system is a central part of innate immunity, but its dysregulated activation is detrimental and results in systemic diseases with overt inflammation. G...
Main Authors: | Kelly Budge, Sergio Dellepiane, Samuel Mon-Wei Yu, Paolo Cravedi |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-01-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2020.599236/full |
Similar Items
-
Complement in Non-Antibody-Mediated Kidney Diseases
by: Andrea Angeletti, et al.
Published: (2017-07-01) -
Association of Glomerular Complement C4c Deposition With the Progression of Diabetic Kidney Disease in Patients With Type 2 Diabetes
by: Suyan Duan, et al.
Published: (2020-09-01) -
Complement C3 and incident hospitalization due to chronic kidney disease: a population-based cohort study
by: Xue Bao, et al.
Published: (2019-02-01) -
The insulin-like growth factor system in chronic kidney disease: Pathophysiology and therapeutic opportunities
by: Youngman Oh
Published: (2012-03-01) -
Establishing equivalent diabetes in male and female Nos3‐deficient mice results in a comparable onset of diabetic kidney injury
by: Lifang Tian, et al.
Published: (2019-09-01)